News

Drs. Jim Heath, Yapeng Su and Jihoon Lee

Metabolic Changes in Plasma and Immune Cells Associated with COVID-19 Severity, May Predict Patient Survival

Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.

Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

COVID-19 Immune Response Study Could Lead to More Effective Treatments

Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.

Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

For Cancer Cells, There Is More Than One Path to Drug Resistance

In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.